Today: 21 May 2026
Salesforce stock price steadies at $191 after AI-driven software selloff — what to watch next
8 February 2026
2 mins read

Salesforce stock price steadies at $191 after AI-driven software selloff — what to watch next

New York, Feb 7, 2026, 18:33 EST — Market’s done for the day.

  • CRM finished Friday up, bouncing back after a tough AI-driven selloff hit software and data stocks.
  • Investors are weighing if the momentum in AI is moving away from applications and toward the “picks-and-shovels” names tied to hardware.
  • Salesforce’s next big mover: results and a conference call set for Feb. 25.

Salesforce (NYSE:CRM) bounced 0.7% higher to finish at $191.35 on Friday, recovering from a tumble to $187.12—its lowest point in a year—before rallying into the close. Earlier in the session, the stock had reached $194.60.

The rebound in the final stretch wasn’t enough to make up for the week’s losses. Salesforce is down roughly 9% for the week—caught up in the growing divide within the AI trade, where hardware and infrastructure names are attracting capital, while software stocks seen as exposed to AI risk are taking the hit. “This divergence is not a vote against AI,” Saxo’s Charu Chanana said. Reuters

Markets remain unsettled. That $600 billion AI investment spree from big tech this year has rekindled worries over how—if at all—companies will turn spending into profits, and investors are still wary of shelling out for expansion. “It got too pricey,” said Andrew Wells, chief investment officer at SanJac Alpha. Reuters

This week’s jolt came straight out of the AI sector. Anthropic rolled out its upgraded Claude Opus 4.6 model Thursday, and pointed to progress on much bigger “token” caps — tokens being the basic text units these systems analyze. The developments fueled bets that emerging AI could eat into business long held by traditional software. “We are excited to partner and actually lower the floor to get more value out of those tools,” Anthropic’s head of product for enterprise Scott White said. Reuters

Salesforce finds itself right at the heart of this debate. The company relies on subscription-based CRM software, usually charging per user seat. That model leaves it vulnerable if clients freeze hiring, trim license counts, or push for more productivity with fewer seats.

Salesforce has its next major update coming Feb. 25, with fourth-quarter and full-year fiscal 2026 results set to drop after the bell. The conference call starts at 5 p.m. ET, according to the company.

Macro could put yet another twist in play first. The U.S. jobs numbers are now set for Feb. 11, with the consumer price index following on Feb. 13, both pushed back after the federal shutdown, S&P Global Market Intelligence says. These are the kind of data points that can shift rate bets and, in turn, move tech valuations.

The challenge for Salesforce stretches beyond the upcoming data release. A picture-perfect quarter might still leave investors uneasy, wrestling with how AI could play out—will it drive up software demand, flatten it into a commodity, or simply redirect spending elsewhere in the tech stack?

Other names in the group have taken a hit too, highlighting a sector-wide pullback rather than just one company’s problem. Still, certain AI-related hardware stocks are proving more resilient—a clear sign that “tech” isn’t moving in lockstep anymore.

Monday, the focus shifts to whether buyers step back into struggling software names and if bonds hold steady before the delayed U.S. numbers land. Next up for Salesforce: its Feb. 25 earnings and call, the clear milestone for CRM stock.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Citi stock jumps 6% as consent-order exit talk builds — what to watch next week
Previous Story

Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings
Next Story

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings

Go toTop